Session » (0934–0964) Systemic Sclerosis & Related Disorders – Basic Science Poster

Date: Monday, November 13, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 0940

A Novel Therapeutic Opportunity in Systemic Sclerosis: The Fibrolytic Activities of a Specialized Macrophage Secretome

9:00AM-11:00AM: Abstract Number: 0934

Anti-fibrotic Effects of MT-5562, a Novel Potent Selective Autotaxin Inhibitor, in Preclinical Studies: Roles of Lysophosphatidic Acid in Autoimmune Diseases and Clues to Treat Skin and Lung Fibrosis in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0963

Anti-Topoisomerase Antibody in dcSSc: Unravelling Its Intracellular Effects in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0943

Attenuation of Fibroblast Activation and Fibrosis by Adropin in a Hedgehog-Dependent Manner

9:00AM-11:00AM: Abstract Number: 0938

Deconvolution of the Molecular Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: A Biomarker Blueprint of Scleroderma Disease Continuum

9:00AM-11:00AM: Abstract Number: 0949

Development of Interstitial Pneumonia with Autoimmune Features in Conditional Tgfb3 Deletion

9:00AM-11:00AM: Abstract Number: 0956

Effects of B Cell Depletion by CD19-targeted CAR-T Cells in a Murine Model of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0947

Fcγ Receptors Define Pro-Phagocytic Macrophages and Trigger Pro-Inflammatory Responses in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0953

Flavin-containing Monooxygenase (FMO3) Links the Gut and Fibrosis in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0942

G Protein-coupled Receptor Kinase 5 in Fibrotic Tissue Remodeling

9:00AM-11:00AM: Abstract Number: 0955

GRB2 Serves as a Viable Target Against Skin Fibrosis in Systemic Sclerosis by Regulating Endothelial Cell Apoptosis

9:00AM-11:00AM: Abstract Number: 0939

HRCT-derived Delta Radiomic Features Classify Response to Anti-Fibrotic Treatment in Experimental and Human Fibrosing Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 0937

IL-4+ and IFN-α+ Profibrotic T Cells Aggravate Systemic Sclerosis via STIM1/STING Signaling in SKG Mice

9:00AM-11:00AM: Abstract Number: 0946

Immunoglobulins G Purified from Systemic Sclerosis Patients Influence Cytoplasmic and Nuclear Proteins Profile in Dermal Fibroblasts

9:00AM-11:00AM: Abstract Number: 0936

Impaired DNA Repair Responses Activate a Novel FOXO1-dependent Metabolic Remodelling in Patients with Progressive Systemic Sclerosis to Promote Fibrosis

9:00AM-11:00AM: Abstract Number: 0950

KL-6 and IL-18 Levels Are Negatively Correlated with Respiratory Function Tests and ILD Extent Assessed on HRCT in Patients with Systemic Sclerosis-related Interstitial Lung Disease (SSc-ILD)

9:00AM-11:00AM: Abstract Number: 0944

Macrophages Regulate Adipocyte Differentiation and Proliferation in Skin Fibrosis

9:00AM-11:00AM: Abstract Number: 0960

MiR-3606-3p Alleviates Skin Fibrosis by Suppressing Fibroblast Inflammation and Migration via Inhibiting GAB1 and ITGAV

9:00AM-11:00AM: Abstract Number: 0948

Nintedanib Alters Fibroblast and Macrophage Diversity in a 3D Skin Model of Systemic Sclerosis (SSc)

9:00AM-11:00AM: Abstract Number: 0954

Non-canonical WNTA Promotes Cytoskeletal Rearrangement and Integrin Alpha V Clustering via JNK and ROCK to Control the Activation of Latent TGFβ

9:00AM-11:00AM: Abstract Number: 0957

Rationale for Targeting Insulin-like Growth Factor Signalling in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0959

Redirecting Macrophage Immunophenotype Attenuates Inflammation and Fibrotic Activation in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0941

RUNX1 Expression and Binding Site Accessibility Is Associated with Increased Disease Severity in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0958

Shared Genetic Susceptibility Between Systemic Sclerosis and Primary Biliary Cholangitis: Analyses from Genome-Wide Association Studies

9:00AM-11:00AM: Abstract Number: 0951

Single Cell Analysis of Transitional B Cells in Systemic Sclerosis Highlights Defective Peripheral Tolerance

9:00AM-11:00AM: Abstract Number: 0935

Sodium Pyruvate Improves Mitochondrial Fitness in SSc Fibroblasts to Prevent Fibroblast-to-myofibroblast Transition and Fibrotic Remodeling

9:00AM-11:00AM: Abstract Number: 0964

Systemic Sclerosis (SSc) Dermal Fibroblasts Show Shortened Primary Cilia Due to Aberrant Aurora a Kinase Activation Independently of Transforming Growth Factor β Signalling

9:00AM-11:00AM: Abstract Number: 0945

The Nuclear Receptor TR4 Orchestrates Cytoskeletal Organization in a Gα12/ROCK-dependent Manner to Promote Myofibroblast Differentiation and Tissue Fibrosis in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0962

Topological Proteomic Differences in Fibrotic and Unaffected Skin in Scleroderma

9:00AM-11:00AM: Abstract Number: 0961

Transcriptomic Analysis of Scleroderma Monocytes Identifies Distinct Clinically Relevant Clusters and Novel Genes Associated with Disease Complications

9:00AM-11:00AM: Abstract Number: 0952

Unraveling the Role of MiR-181 in Skin Fibrosis Pathogenesis by Targeting NUDT21

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].